Efficient in vivo genome editing mediated by stem cells-derived extracellular vesicles carrying designer nucleases
Sylwia Bobis-Wozowicz,Karolina Kania,Kinga Nit,Natalia Blazowska,Katarzyna Kmiotek-Wasylewska,Milena Paw,Elzbieta Karnas,Agnieszka Szyposzynska,Malgorzata Tyszka-Czochara,Olga Woznicka,Dariusz Boruczkowski,Claudio Mussolino,Paweł P. Łabaj,Axel Schambach,Zbigniew Madeja,Toni Cathomen,Ewa K. Zuba-Surma
DOI: https://doi.org/10.1101/2021.02.25.432823
2021-02-26
Abstract:Abstract Precise genome editing using designer nucleases (DNs), such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and the clustered regularly interspaced short palindromic repeat/Cas9 (CRISPR/Cas9) system, has become a method of choice in a variety of biological and biomedical applications in recent years. Notably, efficacy of these systems is currently under scrutiny in about 50 clinical trials. Although high DNs activity in various cell types in vitro has already been achieved, efficient in vivo genome editing remains a challenge. To solve this problem, we employed stem cells-derived extracellular vesicles (EVs) as carriers of DNs. We used umbilical cord-derived mesenchymal stem cells (UC-MSCs) and induced pluripotent stem cells (iPSCs) as EV-producer cells, since they are both applied in regenerative medicine. In our proof-of-concept studies, we achieved up to 50% of EGFP marker gene knockout in vivo using EVs carrying either ZFN, TALEN or the CRISPR/Cas9 system, particularly in the liver. Importantly, we obtained almost 50% of modified alleles in the liver of the experimental animals, when targeting the Pcsk9 gene, whose overexpression is implicated in hypercholesterolemia. Taken together, our data provide strong evidence that stem cells-derived EVs constitute a robust tool in delivering DNs in vivo , which may be harnessed to clinical practice in the future.